Figure 1 | Scientific Reports

Figure 1

From: Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment

Figure 1

Impact on tumor growth inhibition (TGI) across syngeneic models. (A) Response to anti-PD-1 antibody treatment (10 mg/kg) in a panel of syngeneic models (mean % TGI ± SEM) with sensitive models highlighted in red box. (B) Growth curves of MC38, Hepa1–6, CT26 and EMT-6 subcutaneous tumors following depletion of specific immune lineages using anti-CD8 (250 mg/mouse), anti-CD-4 (250 mg/mouse), anti-NK (anti-NK1.1 250 mg/mouse for MC38 and Hepa1-6 or anti-asialo for CT26 and EMT-6) and anti-CD25 (400 mg/mouse) antibodies and Clodronate Liposomes (0.2 ml/mouse) with (C) TGI summarized in a bar plot (% relative to non-treated control). Individual immune cell profiles for MC38 (B) and Hepa1–6 (C) assessed by flow cytometry (% of either live or CD45 + cells) following depletion of specific lineages (Experiment 1).

Back to article page